Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

The pharmaceutical giant's stock has severely lagged the broader market in 2024, falling 2.43% while the S&P 500 has surged ...

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...

Pfizer's quarterly earnings handily beat expectations, a boost for the company as it faces pressure from an activist investor ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...